Abiopharma

🔍 GLENBROOK CAPITAL MANAGEMENT (Executive)

Company: SenesTech, Inc. (SNES)

Report Date: 2026-03-13

Detailed Transactions and Holdings:

• Acquired 146,249 shares of Common Stock, $0.001 par value per share ("Common Stock") at $1.9517 per share (Direct)
  Date: 2026-03-13 | Code: P | equity_swap_involved: 0 | shares_owned_after: 865,850.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 5,060 shares of Common Stock at $1.8562 per share (Direct)
  Date: 2026-03-16 | Code: P | equity_swap_involved: 0 | shares_owned_after: 870,910.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 19,725 shares of Common Stock at $1.7924 per share (Direct)
  Date: 2026-03-17 | Code: P | equity_swap_involved: 0 | shares_owned_after: 890,635.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The amount of securities beneficially owned by the Reporting Person following the transaction that occurred on February 17, 2026, as reported in column 5 of Table I of the Form 4 filed by the Reporting Person on February 19, 2026, was understated by 15,390 shares of Common Stock. This understatment affected the amount of securities beneficially owned by the Reporting Person as reported in column 5 of Table I in all subsequent transactions reported on that Form 4. The amount of securities beneficially owned by the Reporting Person following the transaction reported on this line corrects this understatement.
• F2: The securities to which this filing relates are held directly by PFS Trust ("PFS Trust") and Glenbrook Capital Management Inc. Employee Profit-Sharing Plan ("GCM EPSP"). Glenbrook Capital Management (the "Reporting Person") serves as the investment manager to each of PFS Trust and GCM EPSP. The Reporting Person disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of its pecuniary interest therein, if any.